Guidant boosts drug-eluting stent agenda with $35 million polymer pact
This article was originally published in Clinica
Executive Summary
In a bid to bolster its drug-eluting stent programme, Guidant is to pay $35m for rights to bioabsorbable polymer technology developed by San Diego, California firm MediVas.